Business
Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda in the US
Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda in the
About this update from Cipla Ltd
Mumbai, India , Warren, New Jersey , USA - Invagen Pharmaceuticals Inc , a wholly owned subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA ) announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. (hereinafter referred to as Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), for the United States . As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory. The collaboration reflects both companies' shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies. Commenting on the partnership, Achin Gupta , Managing Director & Global Chief Executive Officer, Cipla , said, 'This partnership reflects Cipla's confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio. By combining Qilu's development strengths with Cipla's commercial presence and patient-centric legacy, we aim to expand access to high-quality biologics for patients across our focus markets.' Marc Falkin , Chief Executive Officer, Cipla North America , said, 'This collaboration is aligned with our strategy to expand our biosimilar portfolio in the coming fiscal years, and we are excited to add QL2107 with Qilu who have been great partners. With our established commercial capabilities, we are well-positioned to successfully launch QL2107, subject to regulatory approval, and help ensure it reaches patients in need while lowering the cost of treatment.' Hanchang Zhang , General Manager of Qilu Pharmaceutical , said, 'We are pleased to establish this partnership with Cipla for QL2107. Qilu boasts a robust and growing biosimilar product pipeline. By combining our R&D and manufacturing strengths with Cipla's U.S . commercial expertise, we aim to bring a high-quality, affordable pembrolizumab biosimilar to U.S . patients.' Contact: Tel: +91 22 41916000 Fax: +91 22 41916120 Email: [email protected] (C) 2026 Electronic News Publishing, source ENP Newswire